Fulcrum Therapeutics (FULC) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$19.6 million.
- Fulcrum Therapeutics' Net Income towards Common Stockholders rose 968.38% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.5 million, marking a year-over-year decrease of 19843.69%. This contributed to the annual value of -$9.7 million for FY2024, which is 9000.87% up from last year.
- Fulcrum Therapeutics' Net Income towards Common Stockholders amounted to -$19.6 million in Q3 2025, which was up 968.38% from -$17.3 million recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year Net Income towards Common Stockholders high stood at $55.4 million for Q2 2024, and its period low was -$34.1 million during Q2 2022.
- For the 5-year period, Fulcrum Therapeutics' Net Income towards Common Stockholders averaged around -$18.6 million, with its median value being -$23.6 million (2021).
- Per our database at Business Quant, Fulcrum Therapeutics' Net Income towards Common Stockholders skyrocketed by 33297.73% in 2024 and then plummeted by 13121.51% in 2025.
- Fulcrum Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$23.5 million in 2021, then dropped by 11.29% to -$26.1 million in 2022, then grew by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then fell by 18.27% to -$19.6 million in 2025.
- Its last three reported values are -$19.6 million in Q3 2025, -$17.3 million for Q2 2025, and -$16.6 million during Q4 2024.